• Department of Intervention, Affiliated Wuxi People's Hospital of Nanjing Medical University, Wuxi, 214023, Jiangsu, P. R. China;
WANG Weidong, Email: Wdoc@sina.com
Export PDF Favorites Scan Get Citation

Objective To investigate the feasibility and safety of DynaCT microwave ablation (MWA) guided by 3D iGuide puncture technology for lung cancer.Methods The clinical data of 19 patients with primary or metastatic lung cancer who underwent DynaCT MWA from June 2019 to December 2020 in our hospital were retrospectively analyzed, including 15 males and 4 females with an average age of 64.9±11.7 years. The technical success rates, adverse reactions and complications, postoperative hospital stay, and local therapeutic efficacy were recorded.Results Technical success rate was 100.0%. The mean time required to target and place the needle was 15.7±3.7 min and the mean ablation time was 5.7±1.6 min. Thirteen patients underwent biopsy synchronously before the ablation, and 10 (76.9%) patients had positive pathological results. The main adverse reactions were pain (7/19, 36.8%), post-ablation syndrome (4/19, 21.1%) and cough (2/19, 10.5%). The minor complications were pneumothorax (6/19, 31.6%), hemorrhage (5/19, 26.3%), pleural effusion (2/19, 10.5%) and cavity (1/19, 5.3%). Three patients had moderate pneumothorax and received closed thoracic drainage. The median hospitalization time after ablation was 2.0 (2.0, 3.0) d, and no patient died during the perioperative period. The initial complete ablation rate was 89.5% (17 patients) and the incomplete ablation rate was 10.5% (2 patients) at 1-month follow-up, and no local progression was observed.Conclusion DynaCT MWA of lung cancer under the guidance of 3D iGuide system is safe and feasible with a high short-term local control rate, but the long-term efficacy remains to be further observed.

Citation: FAN Chen, TANG Haohuan, ZHOU Qi, SUN Feihu, DING Wei, SUN Lei, WANG Weitao, XU Ping, WANG Weidong. Application of DynaCT combined with 3D iGuide puncture technique to microwave ablation of lung cancer. Chinese Journal of Clinical Thoracic and Cardiovascular Surgery, 2023, 30(2): 221-225. doi: 10.7507/1007-4848.202102052 Copy